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INTRODUCTION  
 Febrile neutropenia (FN) is the cause of an 
astounding annual number of cancer-related    
hospitalizations – approximately 60,000 per year 
(Tai et al., 2017). Febrile neutropenia is a compli-
cation of chemotherapy resulting in a temperature 
of 100.4⁰F or greater accompanied by an absolute 
neutrophil count (ANC) below 500 cells/mm3 or 
an ANC below 1000 cells/mm3 and expected to 
decrease below 500 cells/mm3 within 48 hours 
(Patel & West, 2017). Febrile neutropenia occurs 
in approximately 50% of solid tumors and over 
80% of hematologic malignancies. It can occur 
any time during the course of illness, from as  
early as the time of diagnosis to end-stage       
disease. Patients with FN are not only at a higher 
risk of infection, but are more likely to experience 
more severe infection (Patel & West, 2017).  
Therefore, timely administration of empiric     
antibiotics in this subset of patients is crucial for 
reducing morbidity and mortality. However,   
prolonged empiric antimicrobial treatment can 
lead to antimicrobial resistance (e.g. dissemina-
tion of vancomycin-resistant organisms) and   
organ toxicity (e.g. acute kidney injury) (Freifeld 
et al., 2011; Paul et al., 2005). Previous studies 
have failed to show a true clinical advantage with 
the addition of vancomycin to empiric therapy 
(Paul et al., 2005). The European Organization 
for   Research and Treatment of Cancer (EORTC, 
1991) conducted a randomized clinical trial    
consisting of 747 patients (“Vancomycin added to 
empirical combination antibiotic therapy for fever 
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in granulocytopenic cancer patients”). The       
patients were randomized to receive ceftazidime 
and amikacin with or without vancomycin. The 
results showed no significant difference in       
duration of fever or improvement in survival. 
However, antibiotic-associated nephrotoxicity 
was more frequent in the vancomycin arm.      
According to the National Comprehensive Cancer 
Network (NCCN, 2021) and Infectious Diseases 
Society of America (IDSA) guidelines (Freifeld et 
al., 2011), routine addition of vancomycin to   
empiric antimicrobial regimens to treat FN is not 
recommended. Vancomycin is only recommended 
in patients with specific clinical indications such 
as suspected catheter-related infection, hemody-
namic instability, skin or soft-tissue infection,        
colonization with penicillin (PCN)/cephalosporin-
resistant pneumococci or methicillin-resistant 
Staphylococcus aureus (MRSA), preliminary 
gram positive blood cultures, pneumonia, and 
severe and refractory mucositis (summarized in 
Table 1). The guidelines also acknowledge the 
use of vancomycin in the setting of a severe beta 
lactam allergy (Freifeld et al., 2011; NCCN, 
2021). The purpose of this project was to evaluate 
current use of vancomycin for FN and improve 
compliance with a guideline-driven algorithm 
(GDA) to ensure appropriate prescribing and  
therapy duration within a local South Florida 
community hospital.  
  
METHODS 
 This was a biphasic, IRB-reviewed quality 
improvement project evaluating adult patients 
receiving empiric vancomycin therapy for FN. 
This single-center project was conducted at a    
not-for-profit community hospital with over 900 
beds that serves a significant amount of oncology 
patients as it is associated with a large neighbor-
ing cancer center. The community hospital has 84 
inpatient oncology beds between two dedicated 
floors. Phase I of this project was a retrospective 
evaluation of therapy based on National Oncolo-
gy guidelines from January 2019 to December 
2019, while phase II was a prospective evaluation 
of therapy based on guidelines from January 2021 
to March 2021. An algorithm based on national 
guidelines was created to guide pharmacists’      
de-escalation interventions in phase II. The      
algorithm also provided a systematic method to 
assess adherence to national guideline recommen-
dations and incorporated recommendations for 
appropriate initiation and de-escalation of vanco-
mycin empiric therapy. The GDA is summarized 
in Figure 1.  
 Patients were identified using vancomycin 
dispense reports generated through the electronic 
medical record reporting software. Patients were 
included if they were 18 years and older with a 
vancomycin order for the selected indication of 
“neutropenic fever,” “sepsis of unknown origin,” 
or “other.” Patients with one-time orders of     
vancomycin and patients who lacked a document-
ed diagnosis or did not meet the clinical definition 
of FN were excluded. Oncology pharmacists were 
provided with an educational presentation to help 
identify patients meeting inclusion criteria in 
phase II for timely intervention. Data collection 
variables included patient demographics, indica-
tion, pertinent labs and cultures, therapy duration 
and compliance with the GDA. In phase II,    
pharmacists implemented an algorithm to recom-
mend de-escalation or discontinuation of vanco-
mycin as warranted. Data were collected, stored, 
and analyzed using Microsoft Excel. Descriptive 
statistics were used to report results.   
 
RESULTS 
 Forty-eight patients were included in phase I, 
and 32 patients were included in phase II. Subject 
characteristics (summarized in Table 2) were  
similar across phases with the exception of age, 
bone marrow transplant (BMT) status, positive 
cultures, and acute kidney injury. Phase II had a 
higher average patient age and higher percentage 
of BMT patients, while phase I had a higher    
percentage of patients with positive blood        
cultures and acute kidney injury. The percentage 
of patients initiated on vancomycin empiric thera-
py in the presence of guideline-recommended 
clinical indications was 42% in phase I versus 
41% in phase II. The rate of appropriate             
de-escalation increased from 23% in phase I to 
78% in phase II. The overall compliance with the 
GDA, which is defined as both appropriate initia-
tion and de-escalation of empiric vancomycin, 
increased from 15% in phase I to 38% in phase II 
(See Table 3). The average duration of therapy 
decreased from 4.77 days (range: 1 to 16 days) in 
phase I, to 2.69 days (range: 1 to 9 days) in phase 
II. The number of patients who continued on   
empiric vancomycin beyond 48 hours decreased 
from phase I to phase II (See Figure 2). In the 
prospective interventional phase, 18 pharmacy-
initiated interventions were made at an interven-
tion rate of 56%. All interventions were accepted 
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by the physician or advanced practitioner for an 
acceptance rate of 100%. The pharmacy-initiated 
interventions included discontinuation of vanco-
mycin (94.4%) and vancomycin dose optimiza-
tion (5.6%).  
 
DISCUSSION 
 The results of this project show that pharma-
cist intervention resulted in a higher percent  
compliance with national guideline recommenda-
tions and a shorter duration of empiric vancomy-
cin therapy in FN. The largest impact related to 
pharmacist intervention was de-escalation of   
empiric vancomycin therapy. The comparability 
of the total percentage of patients initiated on 
vancomycin with guideline-recommended clinical 
indications among phases highlights the valuable 
role of the pharmacist in de-escalation of empiric 
antimicrobial therapy in the absence of positive 
blood cultures. However, the project had signifi-
cant limitations. Some limitations of this project 
included the small sample size and short duration, 
being that the prospective intervention was only 
three months in duration and occurred during 
weekdays and business hours. Additionally,   
compliance with the GDA was reported as an “all
-or-nothing” approach, meaning that vancomycin 
had to be both initiated in a patient with guideline
-recommended clinical indications as well as     
de-escalated appropriately in order to be consid-
ered compliant. There was little opportunity to 
impact initiation in this particular project, and this 
should be evaluated in the future. Lastly, the   
expansion of oncology services allowed for     
disparity in patient volume between phases due to 
the ability to accommodate more oncology      
patients in phase II. Currently throughout the 
health care system, the sepsis protocol drives the 
use of vancomycin in febrile neutropenia. There-
fore, a future direction for this project is to 
streamline the criteria for vancomycin use in FN 
to specifically include the clinical indications set 
forth by NCCN/IDSA guidelines and separate it 
from the criteria for vancomycin use in sepsis. 
Moreover, a significant number of patients were 
excluded from the project due to being one-time 
orders. Therefore, it may be beneficial to conduct 
a medication-use evaluation of one-time orders 
for vancomycin for FN to evaluate whether there 
is an opportunity to optimize one-time ordering of 
vancomycin in FN.  
 
CONCLUSION 
 Pharmacist interventions had an impact in 
increasing compliance with national guideline 
recommendations and decreasing the duration of 
empiric vancomycin therapy in patients with FN. 
Therefore, clinical pharmacists should routinely 
evaluate empiric vancomycin orders in patients 
with FN for the presence of guideline-
recommended clinical indications and follow up 
to ensure optimal duration of therapy. 
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Table 1 
Summary of Guideline Recommendations for Empiric Addition of Vancomycin in Febrile Neutropenia  
 Clinical Indication  IDSA  NCCN 
Suspected catheter-related infection   
Hemodynamic/clinical instability   
Known colonization with Penicillin/Cephalosporin-resistant 
pneumococci or MRSA 
  
Skin or soft tissue infection   
Gram positive blood cultures   
Pneumonia documented radiographically    
Severe mucositis (if fluoroquinolone prophylaxis AND 
ceftazidime use empirically) 
   
Note. This table summarizes the guideline-recommended clinical indications for empiric addition of 
vancomycin in febrile neutropenia. 
IDSA = Infectious Diseases of America, NCCN = National Comprehensive Cancer Network 
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Average age, years 67 (SD 15.9) 60 (SD 13.6) 
Median ANC, cells/mm3 0.26 (IQR 0.7) 0.29 (IQR 0.6) 
Average Tmax, ⁰C 38.6 (SD 0.8) 38.6 (SD 0.8) 
BMT, n (%) 3 (6.3%) 13 (40.6%) 
PCN allergy, n (%) 5 (10.4%) 5 (15.6%) 
Median baseline SCr, mg/dL 1.1 (IQR 0.7) 0.97 (IQR 0.5) 
Acute kidney injury, n (%) 9 (18.8%) 2 (6.3%) 






Selected indication, n (%) 
Febrile neutropenia 























Note. This table summarizes the subject characteristics in phase I vs. phase II.  
SD = Standard deviation, IQR = Interquartile range 
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Table 3 
Percent Compliance with GDA 
 Characteristic 
 Phase I 
(n=48) 
 Phase II 
(n=32) 
Initiated with Clinical Indications, n (%) 20 (42%) 13 (41%) 
De-escalated within 48 Hours, n (%) 11 (23%) 25 (78%) 
Overall compliance with GDA, n (%) 7 (15%) 12 (38%) 
Note. This table summarizes the percent compliance with the guideline-driven algorithm as it relates to 
initiation, de-escalation, and compliance to the algorithm as a whole. 
Figure 1 
Summary of Guideline-Driven Algorithm 
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Figure 2 
Duration of Therapy 
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